Autopsy report · NCT06851442

Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

“This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 6 months before it stopped.
• 8 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Sponsor type

Industry

Conditions

Breast Cancer

Interventions

TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules

Participants

8

Sites

17

Countries

China

Trials that died the same way

• Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
  “This study was closed to enrollment as of 13 May 2011 due to business reasons. Premature closure was not prompted by any safety or efficacy concerns.” (86% match in meaning)
• Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
  “The study was closed due to the end of funding.” (78% match in meaning)
• Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment
  “Closed due to patient recruitment challenges. No interim analyses were completed; study closure was not related to any concerns about safety or futility.” (78% match in meaning)
• Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
  “The study was closed due to investigator discretion based on the lack of perceived clinical activity observed in the study.” (77% match in meaning)
• A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
  “Study closed due to slow accrual and lack of efficacy.” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.